First, the good news for the Indianapolis-based pharma, from the SERENITY phase 2 study in severely active Crohn’s disease. The trial showed patients treated with the drug mirikizumab saw ...
Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...
Results showed 92.9% of mirikizumab-treated patients who were in clinical remission at 1 year maintained clinical remission at 2 years. Continuous treatment with mirikizumab was associated with ...
Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, has shown efficacy in ulcerative colitis and was approved by the US Food and Drug Administration (FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results